Novo Nordisk bets on life beyond GLP-1 drugs

Novo Nordisk held a capital markets day in London, where CEO Mike Doustdar laid out the company’s strategy for the coming years. The company wants to reduce its dependence on its GLP-1 medicines, the class of drugs that lower blood sugar and promote weight loss. That dependence is substantial: Ozempic and Wegovy account for the vast majority of revenue.

The strategy, reported by STAT News, involves two moves. First, Novo wants to invest more in disease areas beyond diabetes and obesity. Second, the company wants to sell products more directly to consumers, similar to how its obesity medicines are already marketed. Investors responded skeptically: shares fell five percent during the opening remarks.

What GLP-1 already does beyond weight loss

For longevity science, GLP-1 has been of interest for some time. The active compounds in this class, glucagon-like peptide 1 agonists, affect more than blood sugar and appetite. Research suggests effects on inflammation, liver function, and possibly brain protection. Whether those effects are clinically meaningful in healthy aging people has not yet been established.

Novo’s announcement connects to a broader trend: pharmaceutical companies exploring whether their existing drugs may also be effective for aging-related conditions beyond their approved indications.

Five blockbusters, but which ones?

Doustdar named the target of five new blockbusters by 2030, but provided no specific candidates. Investors wanted more detail. That detail is not yet available. This makes the promise a strategy on paper for now, not a clinical reality. Whether Novo can execute the transition depends on what is in its pipeline and how competition in the GLP-1 space develops.

For consumers and patients, little changes in the near term. But a strategic shift by the largest pharmaceutical company in the obesity market is a signal that the era of GLP-1 dominance may be approaching its peak.

Read the original article